<DOC>
	<DOCNO>NCT01016886</DOCNO>
	<brief_summary>While trastuzumab show prevent recurrence breast cancer , woman may also experience damage heart muscle ( include heart failure ) result treatment . The investigator hope learn standard medication use heart failure prevent heart damage cause trastuzumab woman breast cancer . The investigator would also like know way detect damage earlier use magnetic resonance imaging ( MRI ) blood test .</brief_summary>
	<brief_title>Multidisciplinary Approach Novel Therapies Cardiology Oncology Research</brief_title>
	<detailed_description>We propose randomize , placebo-controlled , double-blind study evaluate efficacy ACE-inhibitor ( perindopril ) beta blocker ( bisoprolol ) prevention LV remodeling among woman early breast cancer schedule chemotherapy one year trastuzumab . Participants undergo cardiac MRI baseline 3 12 month , replace usual MUGA , well post-treatment cardiac MRI 24 month evaluate long-term effect .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<mesh_term>Perindopril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Histologic diagnosis HER2 positive breast carcinoma Eligible receive trastuzumab Age &gt; 18 year Able give inform consent No contraindication MRI Known contraindication betablocker therapy Known contraindication ACEI therapy Current treatment ACEI beta blocker indication History heart failure , cardiomyopathy baseline LVEF &lt; 50 %</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>trastuzumab</keyword>
	<keyword>cardiac MRI</keyword>
	<keyword>beta-blocker</keyword>
	<keyword>biomarkers</keyword>
	<keyword>angiotensin convert enzyme inhibitor</keyword>
	<keyword>cardiotoxicity</keyword>
	<keyword>HER2 positive</keyword>
</DOC>